134 related articles for article (PubMed ID: 20181575)
21. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
22. BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
Lewis CR; Fossà SD; Mead G; ten Bokkel Huinink W; Harding MJ; Mill L; Paul J; Jones WG; Rodenburg CJ; Cantwell B
Ann Oncol; 1991 Mar; 2(3):203-11. PubMed ID: 1710482
[TBL] [Abstract][Full Text] [Related]
23. Management of patients with poor-prognosis nonseminomatous germ cell cancer.
Fosså SD; Saeter G; Aass N; Ous S; Stenwig AE; Blomlie V
Oncology; 1990; 47(3):234-40. PubMed ID: 1692984
[TBL] [Abstract][Full Text] [Related]
24. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment.
Pentheroudakis G; De Bono JS; Kaye SB; Simpson A; Paul J; Brown I; Pamenter B; Kirk A; Vasey P; Raby N; Kirk D
BJU Int; 2003 Jul; 92(1):36-42. PubMed ID: 12823380
[TBL] [Abstract][Full Text] [Related]
25. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S; Kerbrat P; Kramar A; Théodore C; Chevreau C; Geoffrois L; Bui NB; Pény J; Caty A; Delva R; Biron P; Fizazi K; Bouzy J; Droz JP;
Ann Oncol; 2007 May; 18(5):917-24. PubMed ID: 17351252
[TBL] [Abstract][Full Text] [Related]
26. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report.
Terakawa T; Miyake H; Muramaki M; Takenaka A; Fujisawa M
Int J Urol; 2010 Oct; 17(10):881-5. PubMed ID: 20731738
[TBL] [Abstract][Full Text] [Related]
27. [A Case of Extragonadal Germ Cell Tumor Treated by Induction Therapy with A Reduced Bep Regimen].
Owa S; Sasaki T; Ishihara M; Watanabe S; Kato M; Sugino Y; Kato M; Masui S; Nishikawa K; Yoshio Y; Kanda H; Sugimura Y; Inoue T
Hinyokika Kiyo; 2020 Dec; 66(12):449-452. PubMed ID: 33435656
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity.
Decatris MP; Wilkinson PM; Welch RS; Metzner M; Morgenstern GR; Dougall M
Ann Oncol; 2000 Apr; 11(4):427-34. PubMed ID: 10847461
[TBL] [Abstract][Full Text] [Related]
29. Acute respiratory distress syndrome in poor prognostic germ cell tumor with multiple lung metastases: a case report.
Naseer MA; Mohammed SS; Das Majumdar SK; Patnaik R; Al Tublani HM; Justin JS; Meddikar JA
Gulf J Oncolog; 2011 Jul; (10):69-71. PubMed ID: 21724533
[TBL] [Abstract][Full Text] [Related]
30. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
Mezvrishvili Z; Managadze L
Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
[TBL] [Abstract][Full Text] [Related]
31. Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis.
Germá Lluch JR; Seguí Palmer MA; Climent Durán MA; Blanco Guerrero R; Fernández Sagarra A; Villavicencio H; Solé Balcells FJ
Eur Urol; 1992; 21(4):287-93. PubMed ID: 1333957
[TBL] [Abstract][Full Text] [Related]
32. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
34. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
35. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
37. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.
Horwich A; Dearnaley DP; Nicholls J; Jay G; Mason M; Harland S; Peckham MJ; Hendry WF
J Clin Oncol; 1991 Jan; 9(1):62-9. PubMed ID: 1702147
[TBL] [Abstract][Full Text] [Related]
39. Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor.
Toyoshima Y; Hara T; Matsui Y; Nagumo Y; Maejima A; Shinoda Y; Komiyama M; Watanabe SI; Fujimoto H
Ann Surg Oncol; 2018 Nov; 25(12):3668-3675. PubMed ID: 30191415
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
